Particle Sciences Expands Biopharmaceutical Development Infrastructure?

Particle Sciences, Inc. has expanded its development capabilities to accommodate the increasing demand for biopharmaceutical formulation and analysis.

Robert Becker, Vice President Biopharmaceutical Sales and Business Development at Particle Sciences, commented: "Our company has been working with biologics for some time, accumulating significant infrastructure and intellectual property. We regularly work with biopharmaceuticals and vaccines ranging from therapeutic proteins, including monoclonal antibodies, to nucleotides, to vaccine antigens and immunomodulators. Adding cell culture and extensive instrumentation to support the testing and characterisations of these biopharmaceuticals was planned for later this year but we’ve accelerated implementation to meet our client’s needs."

With this most recent expansion, Particle Sciences can now run the full gambit of testing including, among others, ELISA, SDS-PAGE, Western blots, image analysis, HPLC, HPLC-MS, ligand-receptor binding assays, cellular proliferation, cytotoxicity and cellular activation assays.

Mark Mitchnick, Particle Sciences’ CEO added: "This expansion augments our existing formulation and sterile manufacturing offerings. With our unique approach to biopharmaceutical formulation and the ability to quickly take our clients into the clinic, Particle Sciences anticipates becoming a leader in large molecule formulation and clinical trial supply."

The company sees a rapidly growing industrial need for these services as biopharmaceutical and biosimilar products become an increasingly important component to the healthcare products market. Particle Sciences’ formulation portfolio enables the broader, more efficient development and application of biopharmaceuticals, and can differentiate products in the biosimilars field.